Samrotamab, also known as LCL100, represents a significant step in cancer investigation. This novel clonal antibody is currently in clinical studies and demonstrates remarkable potential for combating specific cancers, https://aprilcavv154593.blog5.net/92030880/samrotamab-a-promising-monoclonal-molecule-in-development